The conference convened more than 5500 global healthcare stakeholders and HEOR thought leaders representing more than 90 countries from all sectors of healthcare, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.

The ECONCARE team attended this year's conference and participated with the following abstracts/posters:

1) BUDGET IMPACT ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE

2) COST-MINIMIZATION ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE.

3) BUDGET IMPACT ANALYSIS OF A BIOSYNTHETIC MESH FOR ABDOMINAL WALL HERNIA REPAIR IN COMPLEX HERNIAS IN GREECE

4) COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE.

5) INCIDENCE AND COST OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ACENOCOUMAROL, IN GREECE

6) END-OF-LIFE COST FOR LUNG CANCER PATIENTS IN GREECE- A HOSPITAL-BASED RETROSPECTIVE STUDY

7) REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE

8) REAL-WORLD DATA FOR NON-SMALL-CELL LUNG CANCER PATIENTS WITH POSITIVE EGFR MUTATION IN GREECE- PRELIMINARY RESULTS FROM A REGISTRY

9) DOES A STANDARD WILLINGNESS-TO-PAY THRESHOLD EXIST IN GREECE?

The conference convened more than 5500 global healthcare stakeholders and HEOR thought leaders representing more than 90 countries from all sectors of healthcare, including researchers and academicians, assessors and regulators, payers and policymakers, the life sciences industry, healthcare providers, and patient engagement organizations.

The ECONCARE team attended this year's conference and participated with the following abstracts/posters:

1) BUDGET IMPACT ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE

2) COST-MINIMIZATION ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE.

3) BUDGET IMPACT ANALYSIS OF A BIOSYNTHETIC MESH FOR ABDOMINAL WALL HERNIA REPAIR IN COMPLEX HERNIAS IN GREECE

4) COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECE.

5) INCIDENCE AND COST OF BLEEDING EVENTS REQUIRING HOSPITALIZATION IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH ACENOCOUMAROL, IN GREECE

6) END-OF-LIFE COST FOR LUNG CANCER PATIENTS IN GREECE- A HOSPITAL-BASED RETROSPECTIVE STUDY

7) REAL-WORLD DATA OF NIVOLUMAB IN NON-SMALL-CELL LUNG CANCER PATIENTS IN GREECE

8) REAL-WORLD DATA FOR NON-SMALL-CELL LUNG CANCER PATIENTS WITH POSITIVE EGFR MUTATION IN GREECE- PRELIMINARY RESULTS FROM A REGISTRY

9) DOES A STANDARD WILLINGNESS-TO-PAY THRESHOLD EXIST IN GREECE?